Clinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease Population
Study Details
Study Description
Brief Summary
Glycogen storage disease (GSD) patients frequently experience periods of hypoglycemia, putting them at risk for several complications, such as hepatomegaly, adenomas, and cirrhosis. As of now, glycogen storage disease patients are limited to using finger stick glucose meters to monitor their glycemia at home. Diabetes Sentry, a non-invasive hypoglycemia detector designed like a watch, has been available for diabetic patients to non-invasively alert for hypoglycemia, but has never been tested in a GSD population. The investigators propose to test the accuracy of the Diabetes Sentry on patients with GSD types 0, I, III, VI, and IX, by measuring their metabolic markers every two hours, as well as whenever the device alerts for hypoglycemia. If accurate, it could be a useful tool for GSD patients in managing hypoglycemia, both clinically and at home.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
As a participant the following will take place:
The Diabetes Sentry device, which is non-invasive and is worn on the wrist will be used while an inpatient at the University of Florida Health & Shands Hospital. Participants will be monitored for the duration of the observational period on the unit, an expected average will be 24 hours. The device is designed to alarm during periods of perspiration and drops in body temperature. When this occurs, a blood draw will be taken to test for glucose, lactate, and ketone values at those times if there is not an already scheduled clinical care blood draw for normal clinical care.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
GSD 1 These will be subjects with GSD I. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values. |
Device: Diabetes Sentry
The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
Other Names:
|
GSD 0, III, VI, or IX These will be subjects with GSD 0, III, VI, or IX. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values. |
Device: Diabetes Sentry
The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Blood Glucose [At time of alarm (Average of 24 hours)]
glucose level at time of device alarm
- Blood Lactate [At time of alarm (Average of 24 hours)]
lactate level at time of device alarm
- Blood Ketones [At time of alarm (Average of 24 hours)]
ketone level at time of device alarm
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients diagnosed and clinically treated at the University of Florida with any of the glycogen storage diseases I, III, VI, IX, 0 will be asked to participate in this study.
Exclusion Criteria:
- Patients not clinically treated at the University of Florida.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Florida | Gainesville | Florida | United States | 32610 |
Sponsors and Collaborators
- University of Florida
- Diabetes Sentry
Investigators
- Principal Investigator: David A Weinstein, MD, MMSc, Univeristy of Florida
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB201400105